mashviral3m
New Schizophrenia Drug Gets FDA Green Light — First of Its Kind in Over 30 years
The U. S. Food and Drug Administration (FDA) has signed off on Cobenfy, the first revolutionary treatment for schizophrenia ...
Top Stock Movers Now: Wynn Resorts, AT&T, Newmont, and More
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
btimesonline55m
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
New Drug For Schizophrenics Has Experts Excited
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
SchaeffersResearch.com1h
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma ...
The American Journal of Managed Care1h
First Schizophrenia Treatment Approved in Decades Targets Cholinergic Receptors
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...
FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Dow surges over 400 points to all-time high as Wall Street cheers cooling inflation
The Dow jumped more than 400 points Friday to an all-time high after a benign inflation report cleared the way for the ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...